

Can Serum Ferritin Be Effectively Interpreted in the Presence of the Acute-Phase Response?

The paper by Coenen et al. (1) in this issue addresses the detection of iron deficiency in the presence of chronic disease. This is an important diagnostic challenge because of the frequency of the problem as well as its direct effect on patient management. Iron deficiency and the anemia of chronic disease are the most prevalent (75%) causes of anemia in both hospitalized and ambulatory patients (2-4). It is important to differentiate patients who will benefit from therapeutic oral iron from those who not only will not benefit but may even risk iron overload.

The common "gold standard" for the determination of iron stores in clinical practice is the staining of bone marrow aspirate. The goal of the laboratory is to accurately identify iron-deficient patients in such a way as to obviate the need for bone marrow examination in a subset of anemic patients. This is a well-studied clinical problem (5), and most authors agree that no single test of peripheral blood can accurately identify all iron-deficient patients in the presence of an acute-phase response. Two frequently discussed multivariate approaches involve ferritin and mean corpuscular volume (6) or ferritin plus an indicator of the acute-phase response such as erythrocyte sedimentation rate (ESR) or C-reactive protein (7-10).

The anemia associated with acute-phase response or chronic disease has been well characterized in recent reviews (11, 12). Erythrocyte survival is modestly reduced and erythropoiesis is iron-deficient, owing to inadequate release of iron from reticuloendothelial stores. This disorder of iron metabolism is one defining characteristic of the anemia of chronic disease. Interleukin-1 (IL-1), the primary mediator of the acute-phase response, mediates the alterations of acute-phase proteins as well as the characteristic disorder of iron metabolism (13). Using cluster analysis and logistic discriminant analysis, several colleagues and I found an independent mathematical association between ESR, ferritin, and iron stores (7). It is attractive to hypothesize that this relationship reflects concomitant IL-1-mediated changes in acute-phase proteins and iron metabolism. In any event, it is clear that interpretation of serum ferritin values must include consideration of acute-phase response.

Cavill et al. (14) showed that the meaningful interpretation of serum ferritin in the presence of chronic disease must also reflect the degree of anemia. When erythrocyte mass is significantly diminished, less iron circulates in these cells and more should appear in storage loci. This increased storage iron should thus be reflected by an increased concentration of serum ferritin.

Since the publication of our postulated relationship between ESR and serum ferritin (7), the actions of IL-1

and the interrelationships of iron metabolism and the acute-phase proteins have been studied more extensively (15,16). Baynes et al. (16) found that the slope of the relationship between iron stores and ferritin is maintained in several chronic diseases, but with an offset toward higher ferritin concentrations. However, this relationship is different for patients with rheumatoid arthritis in their study group.

All investigators agree that serum ferritin concentrations $<12 \mu\text{g/L}$ indicate iron deficiency. Also, all agree a cutoff of $12 \mu\text{g/L}$ is too low in the presence of an acute-phase response or chronic disease. A review of the literature on rheumatoid arthritic patients in which both ferritin and histologic iron scores are given for each individual reveals 72 patients with ferritin $>160 \mu\text{g/L}$ (17-22). Of these 72 patients, only two (2.7%) showed no bone marrow iron by histologic staining; 70 had iron present. Several of these reports appear in the bibliography of Coenen et al. (1). However, the results of Coenen et al. are distinctly different, showing six (15%) patients with absent iron and five (12.5%) patients with trace iron among 40 patients with chronic disease and ferritin $>160 \mu\text{g/L}$.

Most investigators of iron status have suggested there is some ferritin value indicating low likelihood of iron deficiency in the presence of chronic disease. This suggested value generally varies between 45 and $100 \mu\text{g/L}$ (23-27), which is consistent with our findings (7), in which the graph of ferritin vs ESR suggested that iron deficiency was unlikely if serum ferritin exceeded $80 \mu\text{g/L}$ at the highest ESR tested (150 mm/h). In contrast, Coenen et al. report that an increased concentration of ferritin has poor predictive value for excluding iron deficiency. Many of the reports quoted above are consistent with our data; some are not (28, 29).

The transferability of "discriminant functions," such as the one we proposed (7), from one patient group to others can be fraught with uncertainty (5, 30), owing to (a) the different patients investigated, (b) differences in reference methods or "gold standard," and (c) differences in the test methods used. However, the patients in our study (7) and in that of Coenen et al. (1) seem similar, and it is doubtful that patient selection is sufficient to explain the discrepant findings. The histological iron stains "gold standard" differed in that we used bone marrow aspirations from the posterior superior iliac crest, whereas Coenen et al. used sternal marrow. [Bierman and Kelly (31), studying multiple bone marrow aspirations from the posterior superior iliac crest, suggest that the iliac crest provides a more representative and quantitatively larger marrow source than the sternum.] The ESR method used by Coenen et al. appears identical to that used by us, but the ferritin kits used in the two studies differed. Thus, differences in the reac-

tivity of the antibodies in ferritin kits and differences in the isoferritin makeup of patients' samples may partially account for the lack of transferability of our ferritin vs ESR "discriminant function," although many investigators report reasonably similar performance of most kits measuring basic isoferritins (32-34) and a similar degree of glycosylation and isoferritin makeup in normal and abnormal specimens (15, 35).

Thus, although there are many theoretical reasons for the lack of transferability of the ferritin vs ESR discriminant function from our laboratory to that of Coenen et al., no practical reason is immediately obvious.

Clearly, the discriminant function my colleagues and I presented is useful to find iron deficiency and can obviate the need for bone marrow to detect iron deficiency in some patients. The line drawn in our "discriminant function" was derived by independent mathematical analyses involving cluster analysis and logistic discriminant analysis. The line on our graph of ESR vs ferritin is below that in the paper by Coenen et al., which appears to have been derived from simple linear regression. There do not appear to be any false diagnoses of iron deficiency in our data or in the data of Coenen et al. if our discriminant function is used. Rather, the difference between the two reports is in the likelihood of iron deficiency in patients whose results fall above the discriminant function line, i.e., "false exclusion" of iron deficiency. Such a finding would potentially lead to withholding a beneficial treatment with oral iron.

Publication of the differences between the reports of Coenen et al. and Witte et al. should lead readers and other investigators to evaluate these data in the context of other available data.

References

1. Coenen JLLM, van Diejen-Visser MP, van Pelt J, et al. Measurement of serum ferritin used to predict concentrations of iron in bone marrow in anemia of chronic disease. *Clin Chem* 1991;37:560-63.
2. Prager D. An analysis of hematologic disorders presenting in the private practice of hematology. *Blood* 1972;40:568-73.
3. Paine CJ, Polk A, Eichner ER. Analysis of anemia in medical inpatients. *Am J Med Sci* 1974;286:37-44.
4. Cash JM, Sears DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. *Am J Med* 1989;87:638-44.
5. Beck JR. Touching all the bases in diagnostic test assessment. *Am J Med* 1990;88:203-4.
6. Beck JR, Gibbons AB, Cornwell G, Rawnsley HM. Multivariate approach to predictive diagnosis of bone marrow iron stores. *Am J Clin Pathol* 1978;70:665-70.
7. Witte DL, Kraemer DF, Johnson GF, Dick FR, Hamilton H. Prediction of bone marrow iron findings from tests performed on peripheral blood. *Am J Clin Pathol* 1986;85:202-6.
8. Witte DL, Dick FR, Goeken J, et al. C-reactive protein (CRP) aids interpretation of serum ferritin (FRTN) [Abstract]. *Clin Chem* 1985;31:1011.
9. Witte DL, Angstadt DS, Davis SH, Schrantz RD. Predicting bone marrow iron stores in anemic patients in a community hospital using ferritin and erythrocyte sedimentation rate. *Am J Clin Pathol* 1988;90:85-7.
10. Witte DL. Laboratory tests to confirm or exclude iron deficiency. *Lab Med* 1985;16:671-5.
11. Lipschitz DA. The anemia of chronic disease. *J Am Geriatr Soc*

1990;38:1258-64.

12. Lee GR. The anemia of chronic disease. *Semin Hematol* 1983;20(2):61-80.
13. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. *N Engl J Med* 1984;311:1413-8.
14. Cavill I, Jacobs A, Worwood M. Diagnostic methods for iron status. *Ann Clin Biochem* 1986;23:168-71.
15. Konijn AM, Hershko C. The anaemia of inflammation and chronic disease. In: de Sousa M, Brock JH, eds. *Iron in immunity, cancer and inflammation*. New York: John Wiley & Sons, 1989:111-43.
16. Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin, and C-reactive protein. *Scand J Clin Lab Invest* 1986;46:695-704.
17. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. *N Engl J Med* 1974;290:1213-6.
18. Nielsen OJ, Andersen LS, Ludwigsen E, et al. Anaemia of rheumatoid arthritis: serum erythropoietin concentrations and red cell distribution width in relation to iron status. *Ann Rheum Dis* 1990;49:349-53.
19. Das KC, Sattar MA. Serum and red cell ferritin content in the evaluation of iron status in rheumatoid arthritis. *Scand J Rheumatol* 1989;18:399-405.
20. Bentley DP, Williams P. Serum ferritin concentration as an index of storage iron in rheumatoid arthritis. *J Clin Pathol* 1974;27:786-8.
21. Thomson ABR, Brust R, Ali MAM, Mant MJ, Valberg LS. Iron deficiency in inflammatory bowel disease: diagnostic efficacy of serum ferritin. *Dig Dis* 1978;23:705-9.
22. Hansen TM, Hansen NE, Birgens HS, Holund B, Lorenzen I. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. *Scand J Rheumatol* 1983;12:353-9.
23. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. *West J Med* 1986;145:657-63.
24. Blake DR, Waterworth RF, Bacon PA. Assessment of iron stores in inflammation by assay of serum ferritin concentrations. *Br Med J* 1981;283:1147-8.
25. Cook JD, Skikne BS. Iron deficiency: definition and diagnosis. *J Intern Med* 1989;226:349-55.
26. Vreugdenhil G, Swaak AJG. Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment. *Rheumatol Int* 1990;9:243-57.
27. Rajapakse DNA, Holt PJJ, Perera BS. Diagnosis of true iron deficiency in rheumatoid arthritis. *Ann Rheum Dis* 1980;39:596.
28. Charache S, Gittlelsohn AM, Allen H, et al. Noninvasive assessment of tissue iron stores. *Am J Clin Pathol* 1987;88:333-7.
29. Baynes RD, Bothwell TH, Bezwoda WR, Gear AJ, Atkinson P. Hematologic and iron-related measurements in rheumatoid arthritis. *Am J Clin Pathol* 1987;87:196-200.
30. Holland MR, Jacobs AG. On the transportability of linear discriminant functions. *Ann Clin Biochem* 1982;19:47-51.
31. Bierman HR, Kelly KH. Multiple marrow aspiration in man from the posterior ilium. *Blood* 1956;11:370-4.
32. Wood WG. A comparison of eleven commercial kits for the determination of serum ferritin levels. *J Clin Chem Clin Biochem* 1981;19:947-52.
33. van Oost BA, Willekens FLA, van Neerbos BR, van den Beld B. Implications of using different tissue ferritins as antigens for ferritin in serum: four radioimmunoassay kits compared. *Clin Chem* 1982;28:2429-33.
34. Iacobello C, Ghielmi S, Belloli S, Arosio P, Albertini A. Use of a reference standard to improve the accuracy and precision of seven kits for determination of ferritin in serum. *Clin Chem* 1984;30:298-301.
35. Worwood M. Ferritin in human tissues and serum. *Clin Haematol* 1982;11:275-307.

David L. Witte

Laboratory Control Ltd.
1005 E. Pennsylvania Ave.
Ottumwa, IA 52501